Detalles de la búsqueda
1.
Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Lupus
; 29(13): 1736-1742, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32838621
2.
Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications.
J Assist Reprod Genet
; 35(5): 921-928, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29497952
3.
In utero exposure to Azathioprine in autoimmune disease. Where do we stand?
Autoimmun Rev
; 19(9): 102525, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32240856
4.
A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.
Immunol Res
; 67(6): 478-485, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31873844
5.
What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?
Immunol Res
; 66(5): 577-583, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30159862
6.
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Autoimmun Rev
; 17(12): 1153-1168, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30316994
Resultados
1 -
6
de 6
1
Próxima >
>>